Project Oncology®

Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, …

Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, …

Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shi…

Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shi…

Although CAR T-cell therapies have transformed the treatment of B-cell malignancies, a major logistical and socioeconom…

Although CAR T-cell therapies have transformed the treatment of B-cell malignancies, a major logistical and socioeconom…

Despite the promise of curative therapies for sickle cell disease, access and cost barriers highlight the ongoing need for disease-modifying treatments like hydroxyu…

Despite the promise of curative therapies for sickle cell disease, access and cost barriers highlight the ongoing need for disease-modifying treatments like hydroxyu…

Effective transition from pediatric to adult care should begin as early as age twelve for patients with sickle cell disease, incorporating factors like education, self-ad…

Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as chi…

Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as chi…

Hydroxyurea and chronic transfusions remain cornerstone therapies in managing sickle cell disease, with proven benefits in reducing stroke risk and improving anemia. Howeve…

For decades, hydroxyurea has been the cornerstone therapy for sickle cell disease, but new disease-modifying therapies, curative strategies, and gene therapies are e…

Hydroxyurea and chronic transfusions remain cornerstone therapies in managing sickle cell disease, with proven benefits in reducing stroke risk and improving anemia. Howeve…

Effective transition from pediatric to adult care should begin as early as age twelve for patients with sickle cell disease, incorporating factors like education, self-ad…

For decades, hydroxyurea has been the cornerstone therapy for sickle cell disease, but new disease-modifying therapies, curative strategies, and gene therapies are e…

Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, …

Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, …

As cancer treatment continues to evolve, at-home subcutaneous immunotherapy is at the forefront of decentralized care and research. Here to share his insights on how …